Amgen Reports 58% Lower Death Hazard in Lung Cancer Trial

Amgen's Phase III trial showed that IMDELLTRA plus IMFINZI reduced death risk by 58% vs. IMFINZI alone in extensive-stage small-cell lung cancer, with a hazard ratio of 0.42. The combo also improved progression-free survival and response rates. Amgen plans global regulatory submissions and further studies. According to the company, adverse events were manageable.

Amgen announced that a Phase 3 trial of its drug Imdelltra combined with AstraZeneca's Imfinzi showed a 58% reduction in death risk for extensive-stage small cell lung cancer patients. Median overall survival increased to 21.1 months compared to 12.7 months for Imfinzi alone. Amgen plans to share these findings with global regulators.

Amgen's Imdeltra combined with AstraZeneca's Imfinzi reduced death risk by 58% in late-stage small-cell lung cancer trials. Median survival increased from 12.7 to 21.1 months. Amgen and AstraZeneca are involved in the study, which may change treatment standards.

Amgen announced that adding IMDELLTRA to IMFINZI reduced the hazard of death by 58% in a Phase 3 lung-cancer trial. The company's stock closed at $439.26 on Friday, trading at 19.2 times its adjusted earnings midpoint of $22.90. A 10% share-price gain would require roughly $1.25 billion more in annual adjusted net income, according to TECHi's calculations.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced lung cancer death risk by 58% in a trial. Amgen reports median survival of 21.1 months vs. 12.7 months with Imfinzi alone. Imdelltra sales grew to $288M in Q2 2026, but represents only 2.9% of Amgen's total revenue. Analysts expect Amgen's revenue to grow 4% annually through 2030.

A Phase 3 trial found that a combination of tarlatamab (Amgen) and durvalumab (AstraZeneca) reduced death risk by 58% and extended median survival to 21.1 months in extensive-stage small cell lung cancer patients. The study involved 563 patients across 29 countries. Amgen plans regulatory submissions.